Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Takeda's Senior VP Joins Dementia Discovery Fund

This article was originally published in Scrip

Executive Summary

The Dementia Discovery Fund (DDF), a global investment fund managed by SV Life Sciences, has appointed Tetsuyuki Maruyama chief scientific officer – effective April, 2016. Maruyama joins DDF from Takeda Pharmaceutical Co. Ltd. where he was senior vice president, general manager, pharmaceutical research division for the past five years. Prior to, this he was director of GlaxoSmithKline Plc's neuroscience research centre in Singapore and led Alzheimer's disease target discovery efforts at Merck Sharpe & Dohme, Ltd.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst